Advanced search
Publication Cover
Modern Rheumatology Volume 19, 2009 - Issue 6
Journal homepage
26
Views
4
CrossRef citations to date
0
Altmetric
Original Article

Prospective study of methotrexate treatment for rheumatoid arthritis treated legitimately according to the government recommended 8 mg/week dose

Akira HashiramotoThe Center for Rheumatic Diseases, Kobe University Hospital, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan
,
Kazuko ShiozawaRheumatic Disease Center, Konan Kakogawa Hospital, 1545-1 Saijo, Kamino-cho, Kakogawa 675-854, Japan
,
Yasushi TanakaRheumatic Disease Center, Konan Kakogawa Hospital, 1545-1 Saijo, Kamino-cho, Kakogawa 675-854, Japan
,
Takashi YamaneRheumatic Disease Center, Konan Kakogawa Hospital, 1545-1 Saijo, Kamino-cho, Kakogawa 675-854, Japan
,
Miki MurataRheumatic Disease Center, Konan Kakogawa Hospital, 1545-1 Saijo, Kamino-cho, Kakogawa 675-854, Japan
,
Chihiro TanakaThe Center for Rheumatic Diseases, Kobe University Hospital, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan;Rheumatic Disease Center, Konan Kakogawa Hospital, 1545-1 Saijo, Kamino-cho, Kakogawa 675-854, Japan
,
Yasuhiro TerashimaRheumatic Disease Center, Konan Kakogawa Hospital, 1545-1 Saijo, Kamino-cho, Kakogawa 675-854, Japan
,
Kozo KoyamaRheumatic Disease Center, Konan Kakogawa Hospital, 1545-1 Saijo, Kamino-cho, Kakogawa 675-854, Japan
,
Natsuko NakagawaRheumatic Disease Center, Konan Kakogawa Hospital, 1545-1 Saijo, Kamino-cho, Kakogawa 675-854, Japan
,
Shuji AbeRheumatic Disease Center, Konan Kakogawa Hospital, 1545-1 Saijo, Kamino-cho, Kakogawa 675-854, Japan
,
Rhosuke YoshiharaRheumatic Disease Center, Konan Kakogawa Hospital, 1545-1 Saijo, Kamino-cho, Kakogawa 675-854, Japan
,
Yasuhiro SaegusaDepartment of Orthopedics, Konan Hospital, 1-5-16 Kamokogahara, Higashinada-ku, Kobe 658-0032, Japan
,
Ken TsumiyamaDepartment of Biophysics, Kobe University Graduate School of Health Science, 7-10-2 Tomogaoka, Suma, Kobe 654-0142, Japan
,
Koichiro KomaiDepartment of Biophysics, Kobe University Graduate School of Health Science, 7-10-2 Tomogaoka, Suma, Kobe 654-0142, Japan
,
Yoshitada SakaiThe Center for Rheumatic Diseases, Kobe University Hospital, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan
&
Shunichi ShiozawaThe Center for Rheumatic Diseases, Kobe University Hospital, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan;Global Center of Excellence (G-COE), Kobe University Hospital, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe 650-0017, JapanCorrespondence[email protected]
 show all
Pages 637-642 | Received 17 Mar 2009, Accepted 22 Jun 2009, Published online: 02 Jan 2014

References

  • Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med. 2004;350:2167–79.
  • Kremer JM. Rational use of new and existing disease modifying agents in rheumatoid arthritis. Ann Intern Med. 2001;138:695–706.
  • Hoffmeister RT. Methotrexate therapy in rheumatoid arthritis: 15-year experience. Am J Med. 1983;75:69–73.
  • Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med. 1985;312:818–22.
  • Kremer JM, Lee JK. The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Arthritis Rheum. 1986;29:822–31.
  • Kremer JM. Safety, efficacy, and mortality in a long-term cohort of patients with rheumatoid arthritis taking methotrexate: followup after a mean of 13.3 years. Arthritis Rheum. 1997;40: 984–5.
  • Weinblatt ME, Maier AL, Fraser PA, Colyn JS. Longterm pro-spective study of methotrexate in rheumatoid arthritis: conclu-sions after 132 months of therapy. J Rheumatol. 1998;25:238–42.
  • Yamanaka H, Inoue E, Tanaka E, Nakajima A, Taniguchi A, Terai C, et al. Influence of methotrexate dose on its efficacy and safety in rheumatoid arthritis patients: evidence based on the variety of prescribing approaches among practicing Japanese rheumatologists in a single institute-based large observational cohort (IORRA). Mod Rheumatol. 2007;17:98–105.
  • Yamanaka H, Inoue E, Singh G, Tanaka E, Nakajima A, Taniguchi A, et al. Improvement of disease activity of rheumatoid arthritis patients from 2000 to 2006 in a large observational cohort study IORRA in Japan. Mod Rheumatol. 2007;17:283–9.
  • Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.
  • Baron G, Ravaud P, Samson A, Giraudeau B. Missing data in randomized controlled trials of rheumatoid arthritis with radio-graphic outcomes; a simulation study. Arthritis Rheum. 2008;59:25–31.
  • DAS-score NL. Home of the DAS. Available at: http://www.das-score.n1/.
  • Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N. Com-parison of Disease Activity Score (DAS)28-erythrocyte sedi-mentation rate and DA528-C-reactive protein threshold values. Ann Rheum dis. 2007;66: 407–9.
  • van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol. 2000;27:261–3.
  • Bakker MF, Jacobs JW, Verstappen SM, Bijlsma JW. Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. Ann Rheum Dis. 2007;66[Suppl 31:56–60.
  • Molenaar ET, Voskuyl AE, Dinant HJ, Bezemer PD, Boers M, Dijkmans BA. Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum. 2004;50:36–42.
  • van der Heijde D, Klareskog L, Landewé R, Bruyn GA, Cantagrel A, Durez P, et al. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 2007;56:3928–39.
  • Swierkot J, Szechifiski J. Methotrexate in rheumatoid arthritis. Pharmacol Rep. 2006;58:473–92.
  • Lambert CM, Sandhu S, Lochhead A, Hurst NP, McRorie E, Dhillon V. Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial. Arthritis Rheum. 2004;50:364–71.
  • van Ede AE, Laan RF, Blom HJ, De Abreu RA, van de Putte LB. Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. Semin Arthritis Rheum. 1998;27:277–92.
  • Inokuma S, Sato T, Sagawa A, Matsuda T, Takemura T, Ohtsuka T, et al. Proposals for leflunomide use to avoid lung injury in patients with rheumatoid arthritis. Mod Rheumatol. 2008;18:442–6.
  • Russell AS. Quality-of-life assessment in rheumatoid arthritis. Pharmacoeconomics. 2008;26:831–46.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.